CPA
BVS icon

Capital Performance Advisors’s Bioventus BVS Stock Holding History

Capital Performance Advisors’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-575
Closed -$6.87K – 549
2024
Q3 		$6.87K Buy
+575
New +$4.97K ﹤0.01% 978

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Capital Performance Advisors's BVS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Bioventus (BVS) in Q4 2024, closing a stake of 575 shares — an estimated $6.87K sold.

Capital Performance Advisors first reported a position in BVS in Q3 2024 and held it in 1 quarter. The position peaked at $6.87K in Q3 2024. 151 funds tracked by Wall St. Rank hold BVS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Bioventus position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 575 Bioventus shares in Q4 2024, an estimated $6.87K.
  • Capital Performance Advisors first reported a position in Bioventus in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Bioventus position peaked at $6.87K in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Bioventus as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.